NOXXON Pharma N.V. (ALNOX.PA)
| Previous Close | 0.0901 |
| Open | 0.0901 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0866 - 0.0901 |
| 52 Week Range | 0.0842 - 0.5200 |
| Volume | |
| Avg. Volume | 578,899 |
| Market Cap | 6.706M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2190 |
| Earnings Date | Apr 28, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.24 |
- Business Wire
NOXXON Announces Results of the Extraordinary General Meeting of Shareholders
BERLIN, May 16, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the extraordinary general meeting of shareholders held on Monday, May 16, 2022 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands approved the proposed share consolidation to be implemented by way of parti
- Business Wire
NOXXON Appoints Leading Brain Cancer Experts to Scientific Advisory Board
BERLIN, May 11, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of two leading brain cancer experts to its Scientific Advisory Board (SAB). Prof. Monika Hegi and Dr. Michael Lim and will complement the current SAB and provide strategic and scientific counsel to NOXXON’s lead NOX-A12 program in brain cancer (glioblast
- Business Wire
Noxxon Reports 2021 Financial Results
BERLIN, April 22, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today its financial results for the fiscal year ending December 31, 2021.
